| 货号 | AF1789-SP |
| 别名 | interleukin-28B; IFN-lambda 3; IL28B; IL-28B; IL28C; interferon, lambda 3 | 全称 | Interleukin 28B |
| 反应种属 | Mouse |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects IL‑28B/IFN‑ lambda 3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross-reactivity with recombinant human IL-28A is observed. In Western blots, approximately 35% cross-reactivity (reducing conditions) and approximately 10% cross-reactivity (non-reducing conditions) with recombinant mouse IL-28A is observed. Neutralizes 100% of recombinant mouse IL-28A. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize IL‑28B/IFN‑ lambda 3 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND50) is typically 2-10 µg/mL in the presence of 400 ng/mL Recombinant Mouse IL‑28B/IFN‑ lambda 3. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 282617 (Human); 338374 (Mouse) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant mouse IL‑28B/IFN‑ lambda 3 Asp20-Val193 Accession # Q8CGK6 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% amino acid (aa) sequence identity) and the type I IFN family (15‑19% aa sequence identity) (1‑3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon. The expression of IL-28A, B, and IL-29 is induced by virus infection or double‑stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN‑regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Mouse IL-28B cDNA encodes a 193 amino acid residue precursor protein with a putative 15 aa signal peptide. It shares 61%, 62%, and 52% aa sequence identity with human IL-28A, human IL-28B, and human IL-29, respectively. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IL‑28B/IFN‑ lambda 3 Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IL‑28B/IFN‑ lambda 3 Antibody. Recombinant Mouse IL‑28B/IFN‑ lambda 3 (Catalog # 1789‑ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Mouse IL‑28B/ IFN‑ lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL‑28B/IFN‑ lambda 3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1789). The ND50 is typically 2‑10 µg/mL. |
